Lucas Nogueira de Carvalho Pelegrini, Vanessa Alexandre da Silva, M. Grigoli, I. P. Vatanabe, P. Manzine, M. Cominetti
{"title":"Plasma ADAM10 Levels and their Association with Alzheimer's Disease Diagnosis in Older Adults with Fewer Years of Formal Education.","authors":"Lucas Nogueira de Carvalho Pelegrini, Vanessa Alexandre da Silva, M. Grigoli, I. P. Vatanabe, P. Manzine, M. Cominetti","doi":"10.1159/000538630","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\nLow educational attainment is a potential risk factor for Alzheimer's disease (AD) development. Alpha-secretase ADAM10 plays a central role in AD pathology, attenuating the formation of beta-amyloid peptides and, therefore, their aggregation into senile plaques. This study seeks to investigate ADAM10 as a blood-based biomarker in mild cognitive impairment (MCI) and AD in a diverse group of community-dwelling older adults, focusing on those with limited educational attainment.\n\n\nMETHODS\nParticipants were recruited from public health services. Cognition was evaluated using MMSE and ACE-R batteries. Blood samples were collected to analyze plasma ADAM10 levels. A logistic regression was conducted to verify the influence of plasma ADAM10 on the AD diagnosis.\n\n\nRESULTS\nSignificant differences in age, years of education, prescribed medications, and cognitive test scores were found between the MCI and AD groups. Regarding cognitive performance, both ACE-R and MMSE scores displayed significant differences between groups, with post-hoc analyses highlighting these distinctions, particularly between AD and cognitively healthy individuals. Elevated plasma ADAM10 levels were associated with a 4.5-fold increase in the likelihood of a diagnosis of MCI and a 5.9-fold increase in the likelihood of a diagnosis of AD. These findings suggest that ADAM10 levels in plasma serve as a valuable biomarker for assessing cognitive status in older individuals with low education attainment.\n\n\nCONCLUSION\nThis study underscores the potential utility of plasma ADAM10 levels as a blood-based biomarker for cognitive status, especially in individuals with low educational backgrounds, shedding light on their relevance in AD development and diagnosis.","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia and Geriatric Cognitive Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538630","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Low educational attainment is a potential risk factor for Alzheimer's disease (AD) development. Alpha-secretase ADAM10 plays a central role in AD pathology, attenuating the formation of beta-amyloid peptides and, therefore, their aggregation into senile plaques. This study seeks to investigate ADAM10 as a blood-based biomarker in mild cognitive impairment (MCI) and AD in a diverse group of community-dwelling older adults, focusing on those with limited educational attainment.
METHODS
Participants were recruited from public health services. Cognition was evaluated using MMSE and ACE-R batteries. Blood samples were collected to analyze plasma ADAM10 levels. A logistic regression was conducted to verify the influence of plasma ADAM10 on the AD diagnosis.
RESULTS
Significant differences in age, years of education, prescribed medications, and cognitive test scores were found between the MCI and AD groups. Regarding cognitive performance, both ACE-R and MMSE scores displayed significant differences between groups, with post-hoc analyses highlighting these distinctions, particularly between AD and cognitively healthy individuals. Elevated plasma ADAM10 levels were associated with a 4.5-fold increase in the likelihood of a diagnosis of MCI and a 5.9-fold increase in the likelihood of a diagnosis of AD. These findings suggest that ADAM10 levels in plasma serve as a valuable biomarker for assessing cognitive status in older individuals with low education attainment.
CONCLUSION
This study underscores the potential utility of plasma ADAM10 levels as a blood-based biomarker for cognitive status, especially in individuals with low educational backgrounds, shedding light on their relevance in AD development and diagnosis.
期刊介绍:
As a unique forum devoted exclusively to the study of cognitive dysfunction, ''Dementia and Geriatric Cognitive Disorders'' concentrates on Alzheimer’s and Parkinson’s disease, Huntington’s chorea and other neurodegenerative diseases. The journal draws from diverse related research disciplines such as psychogeriatrics, neuropsychology, clinical neurology, morphology, physiology, genetic molecular biology, pathology, biochemistry, immunology, pharmacology and pharmaceutics. Strong emphasis is placed on the publication of research findings from animal studies which are complemented by clinical and therapeutic experience to give an overall appreciation of the field.